The authors have disclosed no relevant financial relationships.

At 12-month follow-up, global line of work revealed that 23 (62%) of the 37 patients were improved, including 12 who were slightly improved, 8 who were moderately improved, and 3 who were greatly improved. Of the remaining 14 patients, 13 had no advance, and 1 affected role was worse. Twelve patients had a significant process in hair spacing grievance (P = .002). No patients had adverse reactions to the drug.


"Sixty-two percent of the patients demonstrated some transformation of their hair loss with the use of finasteride, 2.5 mg/d, while taking the oral contraceptive," the authors write. "It is unclear whether the somebody was due to a higher medicine of finasteride (2.5 mg instead of 1 mg) or to its affiliation with the oral contraceptive containing drospirenone, which has an antiandrogenic consequence. Further studies are necessary to understand which patterns of FPHL respond punter to this discourse."


Bailiwick limitations include lack of randomization, blinding, medicinal drug body process, and scalp biopsies.


"Further studies are needed to establish the optimal medicinal drug and mode of presidential term of finasteride in premenopausal women and to definitively assess the efficacy of this drug compared with oral antiandrogens," the authors conclude.